HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sarkar, S. D. Articles by Palestro, C. J. Search for Related Content PubMed PubMed Citation Articles by Sarkar, S. D. Articles by Palestro, C. J.

Comparison of ¹²³I and ¹³¹I for Whole-Body Imaging in Thyroid Cancer

¹ Division of Nuclear Medicine, Department of Radiology, Long Island Jewish Medical Center, New Hyde Park, New York

ABSTRACT

We compared the diagnostic sensitivities of ¹²³I and ¹³¹I whole-body imaging in differentiated thyroid cancer. Methods: Twelve thyroidectomized patients (3 previously treated with ¹³¹I) were studied. After a period of thyroid hormone withdrawal, whole-body imaging was performed approximately 24 and 72–96 h after administration of 74–185 MBq (2–5 mCi) ¹²³I and 111–185 MBq (3–5 mCi) ¹³¹I, respectively. Results: Both ¹²³I and ¹³¹I revealed residual thyroid tissue, present in 9 patients. ¹³¹I detected metastases in 5 studies of 4 patients. In 4 of 5 studies, ¹²³I missed metastases shown by ¹³¹I in 8 body regions including the neck, mediastinum, lungs, and bone and detected 3 other sites of metastasis only in retrospect. No lesion was better seen with ¹²³I than with ¹³¹I. Conclusion: Although ¹²³I is adequate for imaging residual thyroid tissue, it appears to be less sensitive than ¹³¹I for imaging thyroid cancer metastases.

Key Words: ¹²³I • ¹³¹I • thyroid cancer

This article has been cited by other articles:

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				S. K. Gerard and H. Q. Dam Stunning with 131I Diagnostic Whole-Body Imaging of Patients with Thyroid Cancer * Dr Dam responds: Radiology, March 1, 2005; 234(3): 972 - 974. [Full Text] [PDF]

				S. K. Gerard, S. Mandel, S. D. Sarkar, C. J. Palestro, and T. P. Kalapparambath 131I Versus 123I for Whole-Body Scanning J. Nucl. Med., July 1, 2003; 44(7): 1194 - 1195. [Full Text] [PDF]